Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer
- 205 Downloads
This study aims to investigate clinical significance of topoisomerase 2A (TOP2A) expression and TOP2A gene change in operable invasive breast cancer. This is a retrospective analysis, which includes 256 patients diagnosed as operable invasive breast cancer. All postoperational waxed specimens were subjected to resectioning for staining. Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2), KI-67, TOP2A expression, and TOP2A gene changes were detected by immunohistochemistry (IHC) and fluorescent in situ hybridization technique (FISH), respectively. Correlation between TOP2A expression and clinicopathological characteristics was also investigated. Effects of TOP2A protein or gene changes on survival rate were detected. Results indicated that 165 were TOP2A positive (64.5 %), and 31 were gene amplification positive (12.1 %). Positive rate of TOP2A expression showed significant correlations with ER, KI-67, and HER-2. The difference of 5-year overall survival (OS) between TOP2A-positive and TOP2A-negative groups did not reach statistical significance (OS: P = 0.321, 85.9 vs. 79.6 %; disease-free survival [DFS]: P = 0.247, 83.3 vs. 75.3 %). Five-year OS in TOP2A amplification group was 68.8 %, which is lower than deficiency and control group (P > 0.05). Subgroup analysis showed no significant differences of OS and DFS either between TOP2A-positive and TOP2A-negative groups or between TOP2A amplification and control group in population of patients with HER-2 amplification, triple negative breast cancer, or hormone-positive breast cancer. In conclusion, positive rate of TOP2A expression correlates significantly with ER, KI-67, and HER-2. However, prognostic significance of either TOP2A expression or TOP2A gene changes in breast cancer and its various subtypes is limited.
KeywordsOperable invasive breast cancer Topoisomerase Immunohistochemistry Situ hybridization technique Clinical significance
This work was supported by a grant from the Henan Science and Technology Bureau (No. 132300410213).
Conflicts of interest
- 3.Sherman-Baust CA, Kuhn E, Valle BL. Shih Iem, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I. A genetically, engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014;233(3):228–37.CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Mohammed ZM, McMillan DC, Elsberger B, Going JJ, Orange C, Mallon E. Doughty, Edwards J. Comparison of visual and automated assessment of KI-67 proliferation and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer. 2012;106(2):383–8.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.Cortesi L, Marcheselli L, Guarneri V, Cirilli C, Braghiroli B, Toss A, et al. Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. Int J Cancer. 2013;132(2):E58–65.CrossRefPubMedGoogle Scholar
- 10.Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, et al. Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Brase JC, Schmidt M, Fischbach T, Sultmann H, Bojar H, Koelbl H, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin Cancer Res. 2010;16:2391–401.CrossRefPubMedGoogle Scholar
- 13.Romero A, Martín M, Cheang MC, Lopez-Asenjo JA, Oliva B, He X, et al. Assessment of topoisomerase II status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol. 2011;178(4):1453–60.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Bhargava R, Lal P, Chen B. HER-2/neu and topoisomerase II_ gene amplification and protein expression in invasive breast carcinomas: chromogenic in situ hybridization and immunohistochemical analyses. Am J ClinPathol. 2005;123(6):889–95.Google Scholar
- 19.Wang YX, Fan Y, Zhang Q. Expression of topomerase IIα protein in different molecular subtypes of breast cancer and their prognostic values. Chin J Clin Oncol. 2012;39(7):382–7.Google Scholar
- 20.Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, et al. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab. J Transl Med. 2012;10(1):212.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl S, Bofin AM. TOP2A gene copy number change in breast cancer. J ClinPathol. 2014;67(5):420–5.Google Scholar